Sartorius Stedim Biotech (EPA: DIM) revenue
Sartorius Stedim Biotech reported revenue of €2,968m for fiscal 2025, 6.7% more than in fiscal 2024 (€2,780m). Since fiscal 2020 its revenue has grown by 55.4%, an average growth of 9.2% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | €2,968m | +6.7% | €525.7m | 17.7% |
| 2024 | €2,780m | +0.2% | €370.6m | 13.3% |
| 2023 | €2,776m | −20.5% | €448.7m | 16.2% |
| 2022 | €3,493m | +21.0% | €995.2m | 28.5% |
| 2021 | €2,887m | +51.1% | €865.4m | 30.0% |
| 2020 | €1,910m | — | €471.7m | 24.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of euros, except per-share amounts.
Questions about the revenue of Sartorius Stedim Biotech
- How much revenue did Sartorius Stedim Biotech make in fiscal 2025?
- Sartorius Stedim Biotech reported revenue of €2,968m for fiscal 2025, compared with €2,780m in fiscal 2024.
- How much has the revenue of Sartorius Stedim Biotech grown?
- Between fiscal 2020 and fiscal 2025 it went from €1,910m to €2,968m: 55.4% more, an average growth of 9.2% a year.
- What was the best year for revenue at Sartorius Stedim Biotech?
- Of its last 6 fiscal years, fiscal 2022, with €3,493m.
- Where do the figures for Sartorius Stedim Biotech come from?
- From the report Sartorius Stedim Biotech files every year in the European single electronic format (ESEF), the one it files with the regulator of its home market. Each fiscal year links to its filing.
Where each figure comes from
From the annual report Sartorius Stedim Biotech files every year in the European single electronic format (ESEF). The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. More on Sartorius Stedim Biotech: the Sartorius Stedim Biotech page · annual accounts · net income.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.